Merck Beats First-Quarter Expectations on Keytruda Strength

United States News News

Merck Beats First-Quarter Expectations on Keytruda Strength
United States Latest News,United States Headlines
  • 📰 Medscape
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 55%

Merck posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and HPV vaccine Gardasil.

-Drugmaker Merck & Co Inc on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus vaccine Gardasil.

The company's revenue fell year-over-year due to a sharp, but expected, drop in sales from COVID pill molnupiravir, and rose more than 10% excluding that drug. Sales for COVID treatment molnupiravir - sold under the brand name Lagevrio - fell to $392 million from $3.2 billion last year. The company has said it expects just $1 billion of molnupiravir sales this year.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Merck beats first-quarter expectations on Keytruda, Gardasil strengthMerck beats first-quarter expectations on Keytruda, Gardasil strengthDrugmaker Merck & Co Inc on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.
Read more »

Merck stock pops premarket after Q1 earnings beatMerck stock pops premarket after Q1 earnings beatMerck & Co. Inc.’s stock rose 2% premarket Thursday, after the company posted better-than-expected first-quarter earnings and offered guidance that topped...
Read more »

Meta Platforms stock rallies on results, Mobileye Global stock sinks and other stocks on the moveMeta Platforms stock rallies on results, Mobileye Global stock sinks and other stocks on the moveCaterpillar and Merck & Co’s stock rise after reporting quarterly results.
Read more »

Merck results beat expectations despite a big drop in sales of Covid antiviral treatmentMerck results beat expectations despite a big drop in sales of Covid antiviral treatmentDespite the drop in molnupiravir sales, Merck's revenue and adjusted earnings for the first quarter beat Wall Street's expectations.
Read more »

Barclays beats profit expectations on credit card boom By ReutersBarclays beats profit expectations on credit card boom By Reuters⚠️BREAKING: *BARCLAYS BEATS Q1 PROFIT EXPECTATIONS ON CREDIT CARD BOOM; SHARES UP 4% $BARC $BCS 🇬🇧🇬🇧
Read more »

Amazon revenue beats on stable online demand, cloud strength By ReutersAmazon revenue beats on stable online demand, cloud strength By Reuters⚠️BREAKING: *AMAZON JUMPS 11% AFTER-HOURS FOLLOWING Q1 EARNINGS AND SALES BEAT $AMZN
Read more »



Render Time: 2025-02-14 18:37:29